Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BioXcel Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BTAI
Nasdaq
8731
https://www.bioxceltherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BioXcel Therapeutics Inc
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
- Mar 25th, 2024 11:00 am
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
- Mar 24th, 2024 12:15 pm
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
- Mar 15th, 2024 11:00 am
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
- Mar 13th, 2024 12:57 pm
Q4 2023 BioXcel Therapeutics Inc Earnings Call
- Mar 13th, 2024 1:48 am
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
- Mar 12th, 2024 11:00 am
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
- Mar 7th, 2024 7:52 pm
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
- Mar 1st, 2024 12:00 pm
15 Hot Penny Stocks On the Move
- Feb 22nd, 2024 5:58 pm
BioXcel Therapeutics Announces Termination of Proposed Public Offering
- Feb 13th, 2024 2:00 pm
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
- Feb 12th, 2024 12:14 pm
BioXcel Therapeutics Announces Proposed Public Offering
- Feb 8th, 2024 9:01 pm
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
- Feb 6th, 2024 12:00 pm
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
- Feb 5th, 2024 12:00 pm
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
- Dec 12th, 2023 12:00 pm
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
- Dec 11th, 2023 12:00 pm
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
- Nov 30th, 2023 12:00 pm
7 Penny Stocks With Low Floats and High Short Interest
- Nov 24th, 2023 11:40 am
BTAI: Alignment with FDA on At-Home Study of BXCL501 in Alzheimer’s Agitation…
- Nov 16th, 2023 2:10 pm
BioXcel Therapeutics Third Quarter 2023 Earnings: Misses Expectations
- Nov 16th, 2023 10:15 am
Scroll